AbbVie Claims Rinvoq Superiority To Dupixent In AD

In a head-to-head study of Rinvoq versus Dupixent in atopic dermatitis, the AbbVie drug showed superiority on a composite endpoint measuring skin clearance and itch resolution.

Head to head battle
Rinvoq shows efficacy edge vs. Dupixent in head-to-head trial • Source: Alamy

More from Clinical Trials

More from R&D